CytoDyn (OTCQB:CYDY) has signed an exclusive Distribution and Supply Agreement with American Regent, a Daiichi Sankyo Group company for the distribution of leronlimab for the treatment of COVID-19 in the U.S.
Under the terms of agreement, CytoDyn will supply leronlimab and receive quarterly payments based on a profit-sharing arrangement.
CytoDyn is currently enrolling a Phase 2b/3 clinical trial for 390 severe and critically ill COVID-19 patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.